Connect with us

Cannabis

5 Key Innovations Driving the Future of Cannabis

Published

on

5 Key Innovations Driving the Future of Cannabis

5 Key Innovations Driving the Future of Cannabis

It’s said that necessity is the mother of invention.

As cannabis breaks into the mainstream, the complex web of regulations surrounding the plant may well be what compels the industry to think outside the box.

Today’s infographic from Valens GroWorks highlights some of the most anticipated areas of technology-based disruption in “cannabiz” – the business behind cannabis.

Potential Industry Game-changers

As the cannabis industry grows, the business behind it must grow as well – and to get an edge, industry players are investing in new technologies and innovative practices that could be industry game-changers.

Here are some of the most disruptive moves happening that could shape the future of cannabis:

Agricultural Technology

As consumers become more discerning, they’ve come to demand premium quality cannabis. That’s why many indoor growers are exploring various means to improve the productivity of cannabis plants.

  • Cloud-controlled lights
    Using cloud-based IoT technology, cultivators can remotely adjust the colors and cycles of growing lights that cannabis plants are exposed to in their operations. Such precise control ensures consistency in plant quality.
  • Tissue culture
    Essentially, tissue culture is the multiplication of a single cannabis tissue into hundreds of identical ones. While this method is impressive, it’s incredibly tricky to get right at scale.

Biotech breeding is another upcoming trend to watch out for. Just like the ubiquitous GMO foods you can find in a grocery store, the genetic manipulation of cannabis plants to strengthen specific effects could take the industry by storm.

Novel Delivery

Millions of patients in North America rely on medical cannabis, which will only intensify as states continue to legalize its use. For the longest time, prescribed cannabis has relied on smoking – but extraction technology is introducing new delivery methods.

  • Vaporizer Pens
    These pocket-sized pens can deliver a controlled cannabis dose, with lower chances of including dangerous chemicals. The latest models include Bluetooth capabilities and smartphone apps to customize vape temperatures, among other features.
  • Oils and Tinctures
    Cannabis concentrates, packaged into capsules or as liquid, can be used in vape pens or ingested directly. They also provide a small, controlled cannabis dose, and act fast in a patient’s system.

Consumer Products

Recreational consumers won’t be left behind. This growing segment is enjoying cannabis-based products in a myriad of ways, made possible by new extraction technologies.

  • Nano-technology
    Water soluble oils demonstrate their potent effects quickly through the bloodstream, instead of relying on the slow-acting respiratory or digestive systems.
  • Topicals
    With a wide range of skincare products in the market, these cannabis-infused lotions can applied to the skin’s surface, where they are absorbed for a relaxing effect.

Cashless Payments

Despite the increasing legality of “cannabiz”, many businesses and their customers prefer to deal with cash. Financial institutions are also wary of investing in cannabis, as it’s still perceived as risky in certain circles.

To that end, fintech has stepped up to the plate. Secure and automated transactions can be made and processed via the blockchain, potentially creating an anonymous and convenient way for consumers and companies to transact.

Data and Analytics

Cannabis is finally coming out of hiding, but records around point-of-sale transactions are still lacking. Providing context for such data to give it meaning is difficult, but lucrative.

Leveraging big data to track the cannabis supply chain has secondary advantages of easing the regulatory process, and putting customer demand into perspective. What’s more, digital transaction data on these consumers also offers future opportunities for businesses to address their needs.

As the cannabis space steadily progresses, cannabis companies that respond and adapt to these broad trends of tech innovation will be poised for success.

Tech innovation and ongoing R&D are ingredients that the industry needs to continue to mature and grow.

– Michael Garbuz, CannRoyalty Corporate Strategist

Subscribe to Visual Capitalist

Thank you!
Given email address is already subscribed, thank you!
Please provide a valid email address.
Please complete the CAPTCHA.
Oops. Something went wrong. Please try again later.

Continue Reading
Comments

Cannabis

The Dramatic Rise and Fall of Cannabis Company Stocks

Published

on

The Dramatic Rise and Fall of Cannabis Company Stocks

The unprecedented expansion of cannabis across North America took the investment world by storm, as investors raced to cash in on the “green rush”.

Yet, even as changing regulations unlock new opportunities, it seems as though the cannabis stock bubble has already burst — at least temporarily.

Today’s visualization dives into the roller coaster of cannabis company stock valuations over the past few years, and which companies remain standing in this hazy market.

A Wild Ride for Cannabis Stocks

The North American Marijuana Index tracks the equally-weighted stocks of leading companies operating in the legal cannabis industry in U.S. and Canada. Companies listed on the index must have at least 50% of their business strategy focused on the legal industry, including ancillary operations that support companies and consumers.

At the tail-end of 2017, the promise of upcoming legalization in two immense markets—California state and Canada—had investors all fired up. The index’s low (105.31 on June 27th, 2017) shot up almost three times to 358.93 by January 8th, 2018.

Things took a sharp turn in the second quarter of 2019, as the expectations for cannabis company stocks encountered a harsh reality post-legalization.

IndexNorth America🇺🇸 U.S.🇨🇦 Canada
52-week High319.73137.07727.25
52-week Low110.1751.40195.73

Note: 52-week period data captures Dec 9th 2018-Dec 9th 2019.

What are the reasons behind such a nosedive? Could the cannabis industry still make a comeback in 2020? We look at some opposing perspectives to answer these questions.

So Much For the Green Rush

The cannabis industry is experiencing significant challenges. In the U.S., legal cannabis faces high taxes—come the new year, consumers in California will see an 80% mark-up on their cannabis at checkout, up from 60%.

North of the border, federal legalization led to immense consumer demand for Canadian cannabis—but supply can’t keep up. To make matters worse, retail stores are slow to roll out, which means Canada is feeling the crunch.

Steep prices, and difficulty purchasing products post-legalization, allow the black market to thrive. It’s clear many cannabis companies have taken a big hit as a result.

According to the Marijuana Index, here are the 10 biggest companies in the space now:

CompanySymbolMarket Cap (US$)Country
Canopy Growth Corp.NYSE: CGC$5.6B🇨🇦 Canada
Curaleaf HoldingsCNSX: CURA$3.67B🇺🇸 United States
GW Pharmaceuticals PLCNASDAQ: GWPH$2.98B🇬🇧 United Kingdom
Aurora Cannabis Inc.TSE: ACB$2.85B🇨🇦 Canada
Green Thumb Industries Inc.CNSX: GTII$2.42B🇺🇸 United States
Cronos Group inc.TSE: CRON$1.83B🇨🇦 Canada
Trulieve Cannabis CorpCNSX: TRUL$1.91B🇺🇸 United States
Tilray Inc. NASDAQ: TLRY$1.46B🇨🇦 Canada
Aphria Inc.TSE: APHA$0.96B🇨🇦 Canada
Harvest Health & Recreation Inc.CNSX: HARV$0.94B🇺🇸 United States

Note: Companies listed on a Canadian index have had their market cap converted from CAD$ to US$. Top 10 companies are based on those listed on the North American Marijuana Index. All values as of Dec 9th, 2019.

Only one company outside of North America—and even the cannabis sector—lands on this list. The UK-based Big Pharma company GW Pharmaceuticals is steadily growing its industry presence, as it currently holds 41 cannabis patents in the U.S. and Canada combined.

Still, even these big players have seen their valuations drop since the industry was at its peak. Unless the aforementioned issues are ironed out, investors may continue to pull their dollars from the cannabis industry.

A psychological shift has taken place from everyone wanting to own (cannabis) to everyone involved now feeling burned. I think many investors are now over it.

Chris Kerlow, portfolio manager at Richardson GMP

On the flip side, some investors aren’t calling it quits quite yet.

Long-Term Prospects Are High

While cannabis seems plagued with issues, some argue that these are simply short-term growing pains and will be solved as the industry matures.

Particularly in the U.S., experts predict that cannabis sales could reach immense heights in the next decade:

  1. $30 billion by 2025 (New Frontier Data)
  2. $50 billion by 2029 (Jefferies Group LLC)
  3. $75 billion by 2030 (Cowen Inc.)
  4. $100 billion by 2029 (Stifel Financial Corp)

Compared to a benchmark of $13.6 billion today, these numbers may seem ambitious—but they’re backed by major industry trends. 2020 could well be the year the market stabilizes, as consumers explore an array of retail options and vote with their wallets.

What’s more, key players in consumer industries—from alcohol and tobacco to beauty and fitness—are making big bets in cannabis and CBD-infused products. A higher number of partnerships could spark the next uptick for the industry’s potential.

The marijuana business is not for the faint of heart. But this is a big long-term game.

——Mark Zekulin, CEO of Canopy Growth Corp.

An Eye on What’s to Come

It’s clear there are differing viewpoints on the future of cannabis companies and their respective investors. As this snapshot of cannabis stocks unfolds and transforms in 2020 and beyond, could companies potentially buck the current trend and bounce back? Or will stocks continue to go up in smoke?

Subscribe to Visual Capitalist

Thank you!
Given email address is already subscribed, thank you!
Please provide a valid email address.
Please complete the CAPTCHA.
Oops. Something went wrong. Please try again later.

Continue Reading

Cannabis

The Big Pharma Takeover of Medical Cannabis

The Big Pharma industry is entering the cannabis space, by swapping patients for patents. But what are the impacts of such a takeover?

Published

on

The Big Pharma Takeover of Medical Cannabis

As evidence of cannabis’ many benefits mounts, so does the interest from the global pharmaceutical industry, known as Big Pharma. The entrance of such behemoths will radically transform the cannabis industry—once heavily stigmatized, it is now a potentially game-changing source of growth for countless companies.

Today’s infographic comes to us from CB2 Insights, and explores how and why the notorious Big Pharma are interested in the nascent cannabis industry.

Who are “Big Pharma”?

The term refers to some of the largest pharmaceutical companies in the world, considered especially influential as a group. To give a sense of their sheer size, the market cap of the top 10 Big Pharma companies is $1.7 trillion—Johnson & Johnson being the largest, with a market capitalization of $374 billion.

So far, Big Pharma has watched the cannabis industry from the sidelines, deterred by regulatory concerns. What we are seeing now is the sleeping giant’s takeover slowly intensifying as more patents, partnerships, and sponsored clinical trials come to fruition.

Could Cannabis be Sold Over the Counter?

The cannabis plant has been used in medicine for 6,000 years. However, there is still considerable debate around the role it plays in healthcare today. There are currently almost 400 active and completed clinical trials worldwide surrounding cannabidiol (CBD), a type of cannabinoid that makes up 40% of the cannabis plant’s extract.

Cannabis relies on CBD’s therapeutic properties, and recent studies suggest it may be useful in combating a variety of health conditions, such as:

  • Epilepsy
  • Schizophrenia
  • Multiple sclerosis
  • Migraines
  • Arthritis
  • Cancer side effects

As of 2019, 33 states and the District of Columbia have legalized cannabis for medical use. Its potential for pain management has led some experts to recommend it as an alternative to addictive painkillers, with one study of 13 states showing opiate-related deaths decreasing by over 33% in the six years since medical cannabis was legalized.

As the industry evolves, data is becoming increasingly important in understanding the potential of cannabis—both as a viable medical treatment, and as a recreational product. The shift away from anecdotal evidence towards big data will inform future policies, and give rise to a new era of consumer education.

Big Pharma’s Foray into Cannabis

Further legalization of cannabis will challenge Big Pharma’s bottom line, and poach more than $4 billion from pharma sales annually. In fact, medical cannabis sales are projected to reach $5.9 billion in 2019, from an estimated 24 million patients.

Seven of Canada’s top 10 cannabis patent holders are major multinational pharmaceutical companies, a trend that is not unique to Canada.

Company Rank🇨🇦 Canadian PatentsCompany Rank🇺🇸 U.S. Patents
1. Novartis211. Abbvie59
2. Pfizer142. Sanofie39
3. GW Pharmaceuticals133. Merck35
4. Ericsson134. Bristol-Myers Squibb34
5. Merck115. GW Pharmaceuticals28
6. Solvay Pharmaceuticals76. Pfizer25
7. Kao Corporation77. Hebrew University of Jerusalem19
8. Ogeda SA78. Roche17
9. Sanofi69. University of Connecticut16
10. University of Connecticut610. U.S. Health and Human Services13

It comes as no surprise that many pharmaceutical giants have already formed strong partnerships with cannabis companies, such as Novartis and Tilray, who will develop and distribute medical cannabis together in legal jurisdictions around the world.

Data is the Missing Link

While the body of knowledge about the many uses of cannabis continue to grow, clinical evidence is key for widespread adoption.

Products backed by data will be a defining criteria for major companies to come into the market en masse. And ultimately, Big Pharma’s entry could accelerate public understanding and confidence in cannabis as a viable option for a range of ailments, and mark the next major milestone for the industry.

Subscribe to Visual Capitalist

Thank you!
Given email address is already subscribed, thank you!
Please provide a valid email address.
Please complete the CAPTCHA.
Oops. Something went wrong. Please try again later.

Continue Reading
Get more Visual Capitalist with VC+

Subscribe

Join the 130,000+ subscribers who receive our daily email

Thank you!
Given email address is already subscribed, thank you!
Please provide a valid email address.
Please complete the CAPTCHA.
Oops. Something went wrong. Please try again later.

Popular